Cellectis SA (NASDAQ:CLLS) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 202,800 shares, an increase of 60.1% from the August 30th total of 126,700 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 114,500 shares, the short-interest ratio is presently 1.8 days.
A number of equities analysts have recently commented on CLLS shares. BTIG Research started coverage on shares of Cellectis in a report on Friday, August 9th. They set a “buy” rating and a $37.00 price target on the stock. Zacks Investment Research upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday, August 26th. BidaskClub lowered shares of Cellectis from a “sell” rating to a “strong sell” rating in a report on Saturday, August 17th. Goldman Sachs Group set a $20.00 price target on shares of Cellectis and gave the stock a “hold” rating in a report on Monday, August 12th. Finally, ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Cellectis presently has an average rating of “Hold” and an average target price of $31.67.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. A.R.T. Advisors LLC bought a new position in Cellectis during the second quarter worth $171,000. Point72 Asset Management L.P. raised its stake in Cellectis by 66.9% during the second quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock worth $2,223,000 after buying an additional 57,100 shares during the last quarter. Aperio Group LLC bought a new position in Cellectis during the second quarter worth $147,000. OneAscent Financial Services LLC bought a new position in Cellectis during the second quarter worth $257,000. Finally, ARK Investment Management LLC raised its stake in Cellectis by 18.1% during the second quarter. ARK Investment Management LLC now owns 1,103,186 shares of the biotechnology company’s stock worth $17,210,000 after buying an additional 169,110 shares during the last quarter. 31.65% of the stock is owned by institutional investors and hedge funds.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The business had revenue of $2.93 million for the quarter, compared to analyst estimates of $3.45 million. Analysts predict that Cellectis will post -2.9 EPS for the current fiscal year.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Recommended Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.